



## ADVANCING PROSTATE CANCER RADIOTHERAPY

### INNOVATIONS & BEST PRACTICES

In an era of rapid advancements in prostate cancer treatment, staying at the forefront of emerging technologies and clinical approaches is essential. Whether you are refining your approach to rectal spacing, evaluating the role of AI in radiotherapy, or considering the latest evidence on post-prostatectomy radiotherapy, this workshop will equip you with practical knowledge to enhance patient care.



**Thursday 21 August, 2025**  
0900 – 1730

#### WORKSHOP CHAIRS

Dr Mario Guerrieri  
Dr Cristian Udovicich  
Dr Jeremy de Leon

#### INTERNATIONAL SPEAKERS

Professor Andrew Loblaw,  
Radiation Oncologist,  
University of Toronto, Canada

Professor Tim Showalter,  
University of Virginia,  
United States



Proudly sponsored by



|           |   |
|-----------|---|
| 0900–0905 | <b>Welcome</b>  |
| 0905–0925 | <b>Role of RT in metastasis directed therapy</b><br>Professor Andrew Loblaw   |
| 0925–0940 | <b>Role of systemic intensification with MDT</b><br>Dr Farshad Kasraei  |
| 0940–0950 | <b>Question &amp; Answer</b>  |
| 0950–1000 | <b>Abstract Presentation</b>  |
| 1000–1030 | <b>The Current Landscape of Australian Genitourinary Trials</b><br>Dr Niluja Thiru & Dr Eric Wegener  |
| 1030–1100 | <b>Morning Tea</b>  |
| 1100–1120 | <b>Focal stereotactic reirradiation for locally recurrent prostate cancer after EBRT or brachytherapy</b><br>A/Professor George Hruby   |
| 1120–1140 | <b>MRI based salvage reirradiation for locally recurrent prostate cancer</b><br>Dr Ee Siang Choong  |
| 1140–1200 | <b>Salvage brachytherapy after prior prostatic radiotherapy</b><br>Dr George Cosman   |
| 1200–1220 | <b>DIL boost: all, some or none?</b><br>Dr Eric Wegener   |
| 1220–1245 | <b>Question &amp; Answer</b>  |
| 1245–1330 | <b>Lunch</b>  |
| 1330–1410 | <b>Panel Discussion – Rectal spacing</b><br><b>Why choose a particular spacer or no spacer, Local versus general anaesthetic, Urologist versus radiation oncologist, Preventing and dealing with complications.</b><br>A/Professor George Hruby, Professor Andrew Loblaw, Dr Mario Guerrieri, A/Professor John Yaxley |
| 1410–1450 | <b>Multimodal Artificial Intelligence testing in prostate cancer</b><br>Professor Tim Showalter   |
| 1450–1510 | <b>Question &amp; Answer</b>  |
| 1510–1530 | <b>Abstract Presentation</b>  |
| 1530–1545 | <b>Afternoon Tea</b>  |
| 1545–1605 | <b>Optimizing Pelvic Nodal Radiotherapy for Prostate Cancer: Techniques, Systemic Therapy, and Side Effect Management</b><br>Dr Niluja Thiru  |
| 1605–1625 | <b>Theranostics in 2025 – Current status and future of theranostics applications in prostate cancer</b><br>Dr Aviral Singh  |
| 1625–1645 | <b>PSMA directed therapies – clinical practice &amp; patient considerations</b><br>Professor Shyam Srinivas   |
| 1645–1700 | <b>Question &amp; Answer</b>  |
| 1700–1730 | <b>Panel Discussion of Controversial Cases in Prostate Cancer</b><br>Professor Andrew Loblaw, Dr Cristian Udovicich, Dr Aviral Singh  |

*\*Program correct at time of publication.*

### FIND OUT MORE

Scan the QR code to learn more about the APCC25 workshops.

For a 10% discount use code **UROLOGY10**

